SCIENTIFIC INDUSTRIES INC Files S-1 Registration Statement

TL;DR

<b>Scientific Industries, Inc. has filed an S-1 registration statement with the SEC, indicating potential future public offerings.</b>

AI Summary

SCIENTIFIC INDUSTRIES INC (SCND) filed a IPO Registration (S-1) with the SEC on March 15, 2024. Scientific Industries, Inc. filed an S-1 registration statement with the SEC. The filing was made on March 15, 2024. The company is incorporated in Delaware and its primary SIC code is 3826 (Laboratory Analytical Instruments). The principal executive offices are located at 80 Orville Drive, Suite 102, Bohemia, New York 11716. Helena Santos is listed as the Chief Executive Officer.

Why It Matters

For investors and stakeholders tracking SCIENTIFIC INDUSTRIES INC, this filing contains several important signals. This S-1 filing signals that Scientific Industries, Inc. is preparing for a potential offering of securities, which could involve raising capital or providing liquidity for existing shareholders. As a smaller reporting company, this filing is a crucial step in its financial and corporate development, potentially impacting its access to capital markets and investor base.

Risk Assessment

Risk Level: low — SCIENTIFIC INDUSTRIES INC shows low risk based on this filing. The filing is an S-1 registration statement, which is a standard procedural document for companies planning to offer securities, and does not inherently contain negative financial or operational information.

Analyst Insight

Monitor future filings for details on the proposed offering, including the number of shares, price range, and use of proceeds.

Key Numbers

• 3826 — SIC Code (Primary Standard Industrial Classification Code Number)
• DE — State of Incorporation (State of incorporation)
• 1231 — Fiscal Year End (Fiscal year end)
• 04-2217279 — IRS Number (I.R.S. Employer Identification No.)
• 80 Orville Drive, Suite 102, Bohemia, New York 11716 — Business Address (Address of principal executive offices)
• 6315674700 — Business Phone (Business phone number)
• 333-278009 — SEC File Number (SEC File Number)
• 2024-03-15 — Filing Date (Date of filing)

Key Players & Entities

• SCIENTIFIC INDUSTRIES INC (company) — Registrant
• Helena Santos (person) — Chief Executive Officer
• John F.F. Watkins (person) — Copies to
• Reitler Kailas & Rosenblatt LLP (company) — Legal Counsel
• 3826 (category) — Primary Standard Industrial Classification Code Number
• DE (location) — State of incorporation
• NY (location) — State of business address
• 2024-03-15 (date) — Filing Date

FAQ

Industry Context

Scientific Industries, Inc. operates within the laboratory analytical instruments sector, a field focused on developing and manufacturing equipment for scientific analysis and research.

Regulatory Implications

The S-1 filing is a standard regulatory document required by the SEC for companies planning to offer securities to the public under the Securities Act of 1933.

What Investors Should Do

1. Review the full S-1 filing for details on the proposed securities offering, including the number of shares, price, and use of proceeds.
2. Analyze the company's business description and risk factors within the S-1 for a deeper understanding of its operations and potential challenges.
3. Track future SEC filings from Scientific Industries, Inc. for updates on the registration statement's effectiveness and any subsequent offering activities.

Key Dates

• 2024-03-15: S-1 Filing — Registration statement filed with the SEC, indicating potential future securities offerings.

Year-Over-Year Comparison

This is an initial S-1 filing, so there is no prior filing of this type to compare against for the purpose of 'vs last filing'.

Key Financial Figures

• $0.05 — 0 shares of our common stock, par value $0.05 per share. We are not selling any share
• $1.71 — our common stock on March 12, 2024 was $1.71 per share. You are urged to obtain curr
• $300,000 — other than a working line of credit of $300,000 with the Company's primary bank. If add
• $4,079,400 — ing sector. We incurred net losses of $4,079,400 and $13,668,100 for the six-month trans
• $13,668,100 — e incurred net losses of $4,079,400 and $13,668,100 for the six-month transition period end
• $18,398,600 — 2022, we had an accumulated deficit of $18,398,600. We expect to continue to incur operati

Filing Documents

• scnd_s1.htm (S-1) — 492KB
• scnd_ex231.htm (EX-23.1) — 2KB
• scnd_ex232.htm (EX-23.2) — 2KB
• scnd_ex107.htm (EX-FILING FEES) — 41KB
• scnd_s1img2.jpg (GRAPHIC) — 4KB
• 0001654954-24-003236.txt (&nbsp;) — 543KB

RISK FACTORS

RISK FACTORS 6 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 12

USE OF PROCEEDS

USE OF PROCEEDS 14 SELLING STOCKHOLDERS 14 PLAN OF DISTRIBUTION 21

MANAGEMENT'S DISCUSSION AND ANALYSIS

MANAGEMENT'S DISCUSSION AND ANALYSIS 22 LEGAL MATTERS 28 EXPERTS 28 WHERE YOU CAN FIND ADDITIONAL INFORMATION 28 DOCUMENTS INCORPORATED BY REFERENCE 28 3 Table of Contents This prospectus is part of a registration statement that we have filed with the Securities and Exchange Commission (the "SEC") pursuant to which the selling stockholders named herein may, from time to time, offer and sell or otherwise dispose of the shares of our common stock covered by this prospectus. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus is delivered or shares of common stock are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus, including the documents incorporated by reference therein, in making your investment decision. You should also read and consider the information in the documents to which we have referred you under the captions "Where You Can Find Additional Information" and "Documents Incorporated by Reference" in this prospectus. We have not authorized any dealer, salesman or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any of our shares of common stock other than the shares of our common stock covered hereby, nor does this prospectus constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction to any person to whom it is unlawful to ma

Use of Proceeds

Use of Proceeds All proceeds from the sale of the shares of common stock under this prospectus will be for the account of the selling stockholders. We will not receive any proceeds from the sale of the common stock by the selling stockholders pursuant to this prospectus. However, we will receive proceeds in connection with the applicable exercise price of the warrant to purchase shares of our common stock, unless any of such warrants are exercised via cashless exercise to the extent provided for in the applicable warrant. See "Use of Proceeds". Over the Counter Common Stock Symbol SCND

Risk Factors

Risk Factors Investing in our common stock involves a high degree of risk. See "Risk Factors" below.

RISK FACTORS

RISK FACTORS Investment in our common stock involves risks. Prior to making a decision about investing in our common stock, you should consider carefully the risk factors incorporated by reference in this prospectus, including the risk factors described in the section entitled "Risk Factors" contained in our most recent Annual Report on Form 10-KT. Those risks and uncertainties are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. If any of these risks actually occur, our business, results of operations and financial condition could suffer. In that event the trading price of our common stock could decline, and you may lose all or part of your investment. In connection with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, important risk factors are identified below that could affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed with respect to such future periods in any current statements. The Company undertakes no obligation to publicly revise any forward-looking announcements to reflect future events or circumstances. Risks Relating to Our Financial Position and Need for Additional Capital We have limited financial resources and we may need to raise additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product discovery and development programs or commercialization efforts. In order to be successful with our product development and commercialization programs, principally as it pertains to our bioprocessing sector, we believe that we will need to continue to invest substantial capital into such programs in the foreseeable future. We expect our total operating expenses to continue to be material in connection

View Full Filing

View this S-1 filing on SEC EDGAR